European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

Karin Jordan; M. Aapro; S. Kaasa; C. I. Ripamonti; F. Scotté; F. Strasser; A. Young; E. Bruera; J. Herrstedt; D. Keefe; B. Laird; D. Walsh; J. Y. Douillard; A. Cervantes

doi:10.1093/annonc/mdx757

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

Karin Jordan^*
, M. Aapro
, S. Kaasa
, C. I. Ripamonti
, F. Scotté
, F. Strasser
, A. Young
, E. Bruera
, J. Herrstedt
, D. Keefe
, B. Laird
, D. Walsh
, J. Y. Douillard
, A. Cervantes

^*Kontaktforfatter

IRS - Sjællands Universitetshospital

Heidelberg University
Clinique de Genolier
Oslo University Hospital
University of Oslo
Norwegian University of Science and Technology
National Cancer Institute of Milan
Foch Hospital
Cantonal Hospital St. Gallen
University of Warwick
The University of Texas MD Anderson Cancer Center
The University of Edinburgh
St Columba's Hospice
Our Lady's Hospice & Care Services
European Society for Medical Oncology
University of Valencia
Københavns Universitet
University of Adelaide

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Formidling

Abstract

Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work.

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	29
Udgave nummer	1
Sider (fra-til)	36-43
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdx757
Status	Udgivet - 1. jan. 2018

Finansiering

KJ: Advisory board and or honoraria for presentations for Merck, MSD, Helsinn, Tesaro, Amgen, Hexal, Pfizer. MA: Grant/Reserch supports: Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva, Vifor. Consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, Vifor and has received honoraria for lectures at symposia (equivalent speaker’s bureau) of Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, JnJ, OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, Vifor. SK: Holds stocks in EIR Solutions. CIR: Honoraria from Amgen for educational programs on ONJ. FS: Roche, Vifor, MSD, Teva, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, AMGEN, Pierre Fabre Oncologie, Tesaro. FS: Unrestricted Industry Grants for Clinical Research (last 10 years) Celgene (Lenalidomide Cachexia trial) Fresenius (Survey parenteral nutrition malignant bowel obstruction) Helsinn (Palliative Research Centre, MENAC Trial, KSSG Cachexia) Participation in company-lead clinical cachexia trials Novartis (BYM338 cachexia trial) Punctual Advisorship (Boards, Expert Meetings) Acacia, ACRAF, Amgen, Baxter, Celgene, Danone, Fresenius, GlaxoSmithKline, Grünenthal, Helsinn, ISIS Global, Millennium/Takeda, Mundipharma, Novartis, Novelpharm, Nycomed, Obexia, Otsuka, Ono, Pharm-Olam, Pfizer, Psioxus, PrIME, Santhera, Sunstone, Teva, Vifor. Honoraria for Speaking Helsinn prIME. AY: Honoraria from MSD, Helsinn, Bayer, Leo Pharma. Educational grant from Bayer. EB: Research grant from Helsinn Pharma. JH: Advisory board activity Tesaro and remuneration SOBI. DK: Advisory Board and stock options: Entrinsic Health Solutions. Advisory Board: Second Genome. BL: Advisory Board for Pfizer and Chugai Pharma. DW: Non-executive Director of Nualtra. J-YD has declared no conflicts of interest. AC: Advisory board and or honoraria for Amgen, Lilly, Novartis, Takeda, Roche, MerckSerono, Servier.

Dokumenter og links

10.1093/annonc/mdx757

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

@article{9bc57f3b6ce84f5b88bba1f8314edbbb,

title = "European Society for Medical Oncology (ESMO) position paper on supportive and palliative care",

abstract = "Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work.",

keywords = "ESMO, Multidisciplinarity, Palliative care, Patient-centred care, Position paper, Supportive care, Terminal Care/methods, Humans, Neoplasms/therapy, Quality of Life, Patient-Centered Care/methods, Palliative Care/methods, Practice Guidelines as Topic",

author = "Karin Jordan and M. Aapro and S. Kaasa and Ripamonti, \{C. I.\} and F. Scott{\'e} and F. Strasser and A. Young and E. Bruera and J. Herrstedt and D. Keefe and B. Laird and D. Walsh and Douillard, \{J. Y.\} and A. Cervantes",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/annonc/mdx757",

language = "English",

volume = "29",

pages = "36--43",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

AU - Jordan, Karin

AU - Aapro, M.

AU - Kaasa, S.

AU - Ripamonti, C. I.

AU - Scotté, F.

AU - Strasser, F.

AU - Young, A.

AU - Bruera, E.

AU - Herrstedt, J.

AU - Keefe, D.

AU - Laird, B.

AU - Walsh, D.

AU - Douillard, J. Y.

AU - Cervantes, A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work.

AB - Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work.

KW - ESMO

KW - Multidisciplinarity

KW - Palliative care

KW - Patient-centred care

KW - Position paper

KW - Supportive care

KW - Terminal Care/methods

KW - Humans

KW - Neoplasms/therapy

KW - Quality of Life

KW - Patient-Centered Care/methods

KW - Palliative Care/methods

KW - Practice Guidelines as Topic

U2 - 10.1093/annonc/mdx757

DO - 10.1093/annonc/mdx757

M3 - Journal article

C2 - 29253069

AN - SCOPUS:85041200208

SN - 0923-7534

VL - 29

SP - 36

EP - 43

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

Abstract

Finansiering

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater